0DOL Stock Overview
A biopharmaceutical company, engages in the research, development, and distribution of dermatological products in Germany, Spain, the United Kingdom, rest of Europe, the United States, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Biofrontera AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.17 |
| 52 Week High | €1.22 |
| 52 Week Low | €1.17 |
| Beta | 0.82 |
| 11 Month Change | 0% |
| 3 Month Change | -3.92% |
| 1 Year Change | n/a |
| 33 Year Change | -59.96% |
| 5 Year Change | -80.12% |
| Change since IPO | -57.38% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0DOL | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 0% | -4.3% | -1.0% |
| 1Y | n/a | 14.8% | 7.1% |
Return vs Industry: Insufficient data to determine how 0DOL performed against the UK Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how 0DOL performed against the UK Market.
Price Volatility
| 0DOL volatility | |
|---|---|
| 0DOL Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.1% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in GB Market | 9.2% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0DOL has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 0DOL's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 108 | n/a | www.biofrontera.com |
Biofrontera AG, a biopharmaceutical company, engages in the research, development, and marketing of dermatological products. Its products include Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carcinoma. The company also develops RhodoLED XL for the treatment of multiple interspersed lesions; and Belixos, a medical skin care series for irritated and sensitive skin.
Biofrontera AG Fundamentals Summary
| 0DOL fundamental statistics | |
|---|---|
| Market cap | €55.26m |
| Earnings (TTM) | -€19.54m |
| Revenue (TTM) | €24.97m |
2.2x
P/S Ratio-2.8x
P/E RatioIs 0DOL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0DOL income statement (TTM) | |
|---|---|
| Revenue | €24.97m |
| Cost of Revenue | €4.90m |
| Gross Profit | €20.08m |
| Other Expenses | €39.62m |
| Earnings | -€19.54m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
Aug 31, 2023
| Earnings per share (EPS) | -0.31 |
| Gross Margin | 80.39% |
| Net Profit Margin | -78.25% |
| Debt/Equity Ratio | 0% |
How did 0DOL perform over the long term?
See historical performance and comparison